Efavirenz/lamivudine/tenofovir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Efavirenz/lamivudine/tenofovir
Combination of
EfavirenzNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
TenofovirNucleoside reverse transcriptase inhibitor
Clinical data
Trade namesTelura
Routes of
administration
By mouth
ATC code

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura, is a fixed dose combination medication for the treatment of HIV/AIDS.[1] It combines efavirenz, lamivudine, and tenofovir.[1] As of 2010 it is a first line option in the developing world.[1] It is taken by mouth.[1]

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[1] Severe side effects may include depression, psychosis, or osteonecrosis.[1] In those with a history of epilepsy, it may increase the frequency of seizures.[1] Greater care should also be taken in those with kidney problems.[1] It is unclear if use during pregnancy is safe.[1][2]

It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] A year of medication is estimated to costs 154 USD in the developing world as of 2011.[1] The combination received tentative approval in the United States in 2014.[4] Its availability and importance is supported by Medecins Sans Frontieres.[5]

References[edit]

  1. ^ a b c d e f g h i j "WHO Model List of Essential Medicines Application" (PDF). WHO. Retrieved 29 June 2017.
  2. ^ "Telura" (PDF). Mylan.in. 2014. Retrieved 13 December 2017.
  3. ^ "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.
  4. ^ "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". FDA. Retrieved 13 December 2017.
  5. ^ "Efavirenz/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets (600/300/300 mg FDC)" (PDF). WHO. p. 17.